Target intelligence / Profile preview

Toxins in gastrointestinal tract (null)

Target
null
Molecular classification
Other (Toxins are not a single molecular entity or protein family, but a broad class of harmful substances produced by various organisms)
01

Overview

"Toxins in gastrointestinal tract" is not a single molecule or receptor but refers broadly to various toxic substances—primarily microbial proteins such as bacterial exotoxins—that can affect the gut. These include enterotoxins from bacteria like *Escherichia coli* and *Vibrio cholerae*, which cause diarrhea by disrupting ion transport and fluid balance across intestinal epithelia. Some toxins bind to specific receptors on gut cells—for example, verotoxin from EHEC binds to receptors on intestinal mucosa—leading to cell injury and disease manifestations such as hemorrhagic colitis and hemolytic–uremic syndrome[3]. The term does not refer to one defined therapeutic target but rather encompasses many different molecules with diverse structures and mechanisms of action. There are actual molecular targets within this context—such as bitter taste receptors that sense certain ingested toxins in the GI tract—but "toxins in gastrointestinal tract" itself is too broad/vague/incorrectly specified to serve as a canonical drug target name[1][3].

02

Mechanism of action

Various mechanisms depending on the specific toxin: - Some bacterial toxins activate guanylate cyclase to increase cGMP and fluid secretion (e.g., E. coli heat-stable enterotoxin)[3]. - Others directly damage epithelial cells or disrupt cellular signaling pathways[3].

03

Biological functions

Other (Toxins disrupt normal physiological processes, often causing cell damage, inflammation, or altered secretion in the gastrointestinal tract)
04

Disease associations

InfectionInflammationOther (e.g., food poisoning, enteric disease)
05

Safety considerations

High toxicityPotential for severe dehydration and organ failure in cases of severe infection[3]
06

Interacting drugs

Null as a group; specific toxins may have antidotes or treatments (e.g., antitoxins for botulinum toxin), but there is no universal drug targeting "toxins" as a class.
07

Biomarkers

Null for the group; individual toxins may be detected by specific assays.

Beyond the preview

Go deeper on Toxins in gastrointestinal tract (null).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Toxins in gastrointestinal tract (null).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call